End of the road for Astellas' darexaban
This article was originally published in Scrip
Astellas has decided to discontinue the development of its oral direct Factor Xa inhibitor darexaban maleate in all indications and markets, pointing to difficulties in finding development partners, rising competition and other pipeline priorities.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.